A late aryl hydrocarbon receptor signal may pause clone growth without extending life
A late pulse of an aryl hydrocarbon receptor ligand may temporarily restrain pathological clones without reducing lifelong cancer risk or extending life. A lasting reduction in tumour-forming potential after withdrawal together with longer remaining life would refute this hypothesis
Stage of verification
- Hypothesis published2026-10-05
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Rhythm or programme
Cell proliferation
The production of new cells through cell division
Where this hypothesis actsPathological cell clones during exposure to a regeneration-completion mimetic
Hypotheses on this target 2
Inhibition1
Activation
Function preservation
Feedback restoration
Rhythm restoration
Direct measurement
What is proposed
Temporarily suppress division of cells in pathological clones
HowA late pulse of an aryl hydrocarbon receptor ligand, followed by complete withdrawal to test whether growth resumes
Possible result
Possible smaller clones during exposure, followed by renewed growth without a lasting survival advantage
From the recordограничение видимого размера патологических клонов отражает обратимое торможение их деления.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Keeping abnormal cells from multiplying during tissue repair may not make an animal live longer. The unexpected move is to propose that an intervention intended to finish repair merely pauses growth while leaving the cells capable of forming tumors once treatment ends. This is a hypothesis generated by the pipeline, not a measured result.
- A proposed late pulse of a ligand, a chemical that binds a receptor, activates the aryl hydrocarbon receptor after early tissue repair.
- The receptor signal is proposed to move abnormal cells from active division into a temporary pause, rather than a lasting loss of growth capacity.
- The paused cells are proposed to retain their ability to form tumors despite producing smaller cell groups during treatment.
- Removing the signal is predicted to let the retained abnormal cells resume growth.
- The temporary growth difference is predicted to leave lifetime cancer risk and survival comparable to those under an intervention that strengthens repair.
A patch of weeds can stay small while mowing continues because its roots remain. Once mowing stops, growth can resume.
Where the picture breaks: Mowing removes visible growth, whereas the proposed treatment slows cell division. The picture cannot establish whether the cells retain tumor-forming ability or whether delayed growth changes lifespan.
- Master questionstep 01 of 04
Interventions that imitate beneficial natural bodily processes are sought as possible ways to extend life.
Rests on: The stated goal is to generate new hypotheses about which natural processes to reproduce, how to reproduce them, and why doing so might extend life.
Stated in the chain - Goal pillarstep 02 of 04
The intended output is a defined set of new interventions that imitate natural bodily processes to extend life.
Rests on: The master question explicitly requests new candidate interventions and explanations for their possible effects on lifespan.
Stated in the chain - Gap questionstep 03 of 04
Timely completion of tissue repair might extend life more than stronger repair if both restore tissue equally well at first, but only completion limits later growth of pathological clones, groups of abnormal cells descended from a common ancestor cell.
Rests on: The preceding goal calls for candidate processes to imitate, but supplies no evidence selecting completion of repair over stronger repair.
AssumptionThe comparison takes as its premise that early repair can be matched while later expansion of abnormal cell groups differs. Neither the preceding stages nor the supplied source establishes that premise.
- Hypothesisstep 04 of 04
A late signal through the aryl hydrocarbon receptor, a cellular protein that responds to certain chemicals and changes gene activity, might temporarily slow abnormal cell division without removing the cells' ability to form tumors. Smaller abnormal cell groups during treatment could therefore coexist with no lasting survival advantage.
Rests on: The preceding question separates early tissue recovery from later abnormal growth and lifespan. The endpoint introduces reversible growth restraint as a proposed explanation for why smaller cell groups might not deliver longer life.
AssumptionThe proposed mechanism assumes that growth restraint is reversible and that tumor-forming ability persists. These are premises to test, not findings established by the earlier stages or screened source.
What is carried, and what is not. None of the five proposed mechanism links is established by the supplied screened source. S1, a 2013 paper in Toxicological Sciences available here only through abstract-level material, reports inhibited heart regeneration in adult zebrafish; its treatment preceded injury and its observation covered 21 days, so it does not establish a late, reversible effect on abnormal cell groups or the full sequence through lifetime survival.S1
Where the reasoning is carried by something unstated · 2
- Gap question. The comparison takes as its premise that early repair can be matched while later expansion of abnormal cell groups differs. Neither the preceding stages nor the supplied source establishes that premise.
- Hypothesis. The proposed mechanism assumes that growth restraint is reversible and that tumor-forming ability persists. These are premises to test, not findings established by the earlier stages or screened source.
How a result here could mislead · 3
- Poor growth after treatment withdrawal could be mistaken for lasting protection if the treatment's effect has not actually ended. What closes it: The comparison requires evidence that exposure and its continuing growth-suppressing effect have ceased before regrowth is assessed in the same environment. The supplied material does not specify how complete withdrawal would be verified.
- Regrowth in organoids, laboratory-grown three-dimensional tissue models, could be treated as proof that the cells have unchanged tumor-forming ability. What closes it: Growth recovery and tumor-forming ability must be assessed separately after withdrawal. The hypothesis predicts both, but the supplied test description specifies only the organoid comparison for regrowth.
- A statistically inconclusive survival difference could be read as proof that treatment provides no lifespan benefit. What closes it: Old mice require follow-up through the end of life, and the analysis must specify beforehand what size of survival benefit the study can meaningfully exclude. No sample size or such criterion is supplied.
What would make this wrong. A lasting reduction in tumor-forming ability after complete treatment withdrawal, together with longer remaining life than under the repair-strengthening intervention despite matched early recovery, would contradict the proposed combination of reversible restraint and no survival benefit. That observation would not by itself identify which rival mechanism caused the lasting protection.
What it would change. If this hypothesis held, a smaller abnormal cell population during treatment would not by itself justify calling a repair-mimicking intervention life-extending. Candidate interventions would need to be assessed for persistence of their effects after withdrawal and for actual survival outcomes. Even that result would not establish that all ways of completing repair fail: the rival proposals invoke lasting changes in cells or their surroundings, and effects in humans would remain unestablished.
Sources read · 1
TCDD inhibits heart regeneration in adult zebrafish. · Toxicological sciences : an official journal of the Society of Toxicology · 2013
“Adult male zebrafish were injected with vehicle (control) or TCDD (70ng/g, ip) 1 day prior to partial amputation of the ventricle apex.”
Does not settle: Открытыми остаются последствия позднего сигнала арилуглеводородного рецептора, обратимость торможения деления патологических клонов, возобновление опухолевого роста после отмены воздействия, пожизненная вероятность злокачественного исхода и продолжительность жизни. Исследование описывает введение TCDD до повреждения сердца у взрослых самцов данио-рерио и восстановление миокарда в течение 21 дня.
The gap this hypothesis explains
Two established results predict opposite outcomes, and both cannot be right.
Can mimicking timely repair completion extend life more than boosting repair by limiting later growth of abnormal cell groups?
Original wording · exactly as the pipeline generated it
Может ли миметик своевременного завершения регенерации продлевать жизнь сильнее миметика её усиления, если при одинаковом раннем восстановлении только первый ограничивает последующее расширение патологических клонов?
What this question is asking
The question compares two ways of copying the body's tissue-repair processes: strengthening repair and bringing it to a timely end. It asks whether repeated treatments that promote completion could extend remaining life more than treatments that strengthen repair, when both restore the tissue's protective barrier equally well at first. It assumes that only the completion treatment limits the later expansion of pathological clones, meaning groups of cells descended from one cell that have disease-associated properties. It also asks whether tissue aging changes which phase of repair determines the long-term benefit or harm.
- Mimetic
- An intervention intended to reproduce some effect of a natural biological process. Here it refers to copying either stronger tissue repair or its timely completion; no particular substance or intervention is specified.
- Regeneration or tissue repair
- The processes through which damaged tissue recovers. The question distinguishes an early period of recovery from the later ending of repair activity, without establishing precise boundaries between these phases.
- Timely repair completion
- Ending repair activity at a time that preserves its useful recovery effects. The supplied material does not specify how that time is recognized or measured.
- Tissue barrier
- A tissue's protective separation between compartments or between the body and its surroundings. Restoring this function is the proposed early benefit, but the specific tissue and measurement are not identified.
- Pathological clone
- A group of cells descended from a common ancestor cell and described as having disease-associated properties. Clone expansion means that this group grows; the input does not specify which properties make a clone pathological or whether every such clone leads to cancer.
- Remaining lifespan
- The length of life after a specified starting point, such as treatment initiation. It is distinct from early tissue recovery or the amount of abnormal cell growth.
- Tissue aging
- Changes in tissue as it grows older. The question asks whether these changes alter the treatment comparison, but supplies no age categories or measure of tissue aging.
- Signaling pathway
- A connected sequence of cellular signals that influences what cells do. S4 distinguishes which repair-related pathway is active from how long that activity continues.
- Stem cell
- A cell capable of maintaining a cell supply and producing cells that contribute to tissue renewal. S2's model concerns the subset activated in association with repair, rather than all stem cells.
- Time-weighted measure
- A measure that accounts for how long different values persist. In S2, the prediction concerns activated cell numbers over time rather than a single cell count.
- Inflammation and its resolution
- Inflammation is a biological response to injury or harmful stimuli; resolution is the process by which that response ends. S3 hypothesizes impaired resolution, which is related to, but does not establish, the proposed comparison of repair treatments.
- Mutation
- A change in a cell's genetic material. S3 hypothesizes a type of mutation that interferes with the ending of inflammation.
- Cancer-promoting or carcinogenic
- Contributing to the development of cancer. S4 uses this outcome to distinguish potentially harmful prolonged repair signaling from safe regeneration; it does not measure the lifespan effects of the proposed treatments.
- Acute and chronic injury
- Acute injury occurs over a relatively short period, while chronic injury persists or recurs. These are the injury contexts identified for S4, rather than specified treatment schedules.
At equal early recovery, only a mimetic of timely regeneration completion limits subsequent expansion of pathological clones.
A mimetic is a treatment intended to reproduce a natural process; here, the two processes are strengthening tissue repair and ending it at the appropriate time. The assumption is that both treatments initially restore tissue function equally well, but only the completion treatment restrains later growth of disease-associated cell families. If established, this would make later cell growth a possible explanation for a difference in remaining lifespan.
S4 supports a narrower timing-related proposition: in its discussion of liver cancer, it states that the duration of repair-related signaling determines whether regeneration remains safe or becomes cancer-promoting. It does not establish equal early recovery under two mimetics, or that only a completion mimetic limits pathological clones. S2 supplies a theoretical connection between sustained activation of repair-associated stem cells and cancer risk, rather than evidence for this treatment comparison. The supplied sources therefore support part of the rationale, but not the asserted comparative result.S4S2
The same question asked without the part nothing read establishes:
- When two treatments restore a tissue barrier equally well at first, does mimicking timely repair completion extend remaining life more than strengthening repair?
- How do treatments that promote repair completion versus stronger repair differ in later abnormal cell expansion and remaining lifespan?
- Does tissue aging change the long-term effects of strengthening repair compared with promoting its timely completion?
- Timely completion extends life more Under the question's assumptions, both treatments would deliver the same early recovery, while the completion treatment would leave less subsequent abnormal cell expansion. A longer remaining lifespan would be consistent with that later difference outweighing any benefit of continued repair, although the lifespan difference alone would not prove its cause.
- Both extend life equally Even if the completion treatment limited abnormal cell expansion more effectively, that difference would not produce a greater lifespan benefit over the period measured. Early repair, later cell growth and remaining lifespan would therefore be distinct outcomes rather than interchangeable measures of success.
- Stronger repair extends life more Under the same assumed early recovery and clone-growth difference, stronger repair would nevertheless produce the better survival outcome. This would mean that restricting abnormal cell expansion was insufficient to determine the overall lifespan effect; the supplied sources do not establish what would account for that result.
- The ranking changes with tissue age The same early recovery and later difference in abnormal cell growth could accompany different lifespan rankings in younger and older tissue. A result established at one tissue age would then fail to settle the comparison at another; the supplied sources do not establish whether such a reversal occurs.
The proposed benefit begins with restoring a damaged tissue barrier, allowing the tissue to perform its protective role again. The question then separates that early recovery from what happens to abnormal cell groups afterward. If equally effective early repair is followed by different amounts of harmful cell expansion, early recovery alone would not establish which treatment has the better long-term outcome. However, even less abnormal cell expansion would not by itself establish longer life; that final connection remains unmeasured in the supplied evidence.
S-узлы уровня RL-1 поддерживают усиление регенерации, её последующее торможение и возможность клонального отбора; общий долгосрочный исход неизвестен.
Повторные циклы миметика восстанавливают барьер и увеличивают оставшуюся жизнь при отсутствии ускоренного расширения патологических клонов.
Не установлено, какая фаза определяет знак долгосрочного эффекта при одинаковой ранней пользе и меняется ли это со старением ткани.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Предполагаемое преимущество миметика завершения регенерации по продолжительности жизни может отсутствовать: ограничение видимого размера патологических клонов отражает обратимое торможение их деления. Клетки сохраняют способность к опухолевому росту и возобновляют его после отмены воздействия. Поэтому поздний импульс лиганда арилуглеводородного рецептора может давать одинаковое раннее восстановление и меньшие клоны во время наблюдения, сохраняя прежнюю пожизненную вероятность злокачественного исхода. Гипотеза касается разрыва между реальным временным ограничением роста и отсутствующим выигрышем жизни. Она проверяет SPV_2 и предсказывает отсутствие её устойчивого увеличения относительно миметика усиления.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
После полного прекращения воздействия патологические линии из обеих групп покажут сопоставимую способность к повторному росту в общей среде и сопоставимую опухолеобразующую способность. При продолжительном наблюдении до конца жизни различие в размерах клонов не перейдёт в преимущество общей выживаемости. Устойчивое уменьшение опухолевого потенциала после отмены вместе с увеличением оставшейся жизни опровергнет эту гипотезу в пользу одного из механизмов полноценного завершения.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies comparable regrowth and tumor-forming capacity after exposure ends, no overall survival advantage, and an explicit rejection condition combining sustained reduction in tumor potential with increased remaining lifespan. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Органоиды позволяют сравнивать возобновление роста после отмены в одинаковой среде. Проверка отсутствия выигрыша жизни требует полного наблюдения старых мышей; равенство промежуточных маркеров или статистически незначимое различие в небольшой выборке такого вывода не обеспечивает.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
После полного прекращения воздействия патологические линии из обеих групп покажут сопоставимую способность к повторному росту в общей среде и сопоставимую опухолеобразующую способность. При продолжительном наблюдении до конца жизни различие в размерах клонов не перейдёт в преимущество общей выживаемости. Устойчивое уменьшение опухолевого потенциала после отмены вместе с увеличением оставшейся жизни опровергнет эту гипотезу в пользу одного из механизмов полноценного завершения.
- Rival 01 of 04What would separate them
Brief breaks in genetic material may complete intestinal cell maturation and curb harmful growth predicts: При одинаковом раннем восстановлении и одинаковом позднем снижении пролиферации выключение каталитической активности CAD устранит устойчивую дифференцировку и последующее ограничение патологических линий. Возвращение кратковременной активности нормального CAD восстановит оба эффекта; каталитически неактивный вариант окажется бесполезен. Решающее наблюдение: клетки с зарегистрированными кратковременными разрывами останутся живыми, завершат дифференцировку и дадут меньше патологических потомков. Если они преимущественно погибают либо польза сохраняется при выключенном CAD, предложенный механизм опровергнут.
- Rival 02 of 04What would separate them
Timely regeneration completion may limit harmful clones by reducing mobile DNA insertions predicts: При равном суммарном числе делений позднее подавление LINE-1 уменьшит число новых подтверждённых вставок и патологическое расширение линий, сохранив раннее восстановление. Оно также устранит дополнительное преимущество миметика завершения, если оба действуют через один механизм. Напротив, сохранение преимущества завершения при практически устранённой ретротранспозиции опровергнет её определяющую роль. Перестановка последовательности циклов при одинаковом наборе нагрузок отдельно проверит предсказание модели накопления.
- Rival 03 of 04What would separate them
Restoring intestinal alkaline phosphatase may limit pathological growth after regeneration predicts: При одинаковой проницаемости эпителия, одинаковом содержании кислорода и одинаковом количестве бактерий активный фермент уменьшит воспалительную активность кишечного содержимого и позднее расширение патологических линий; каталитически неактивный фермент этого не сделает. Подавление эндогенной кишечной щелочной фосфатазы устранит преимущество завершения, а добавление активного фермента восстановит его. Сохранение преимущества при отсутствии измеримого дефосфорилирования опровергнет гипотезу.
- Rival 04 of 04What would separate them
Restoring oxygen consumption in colon cells may limit pathological clones after regeneration predicts: При одинаковом раннем восстановлении и сохранённой активности кишечной щелочной фосфатазы преимущество позднего миметика исчезнет при избирательном подавлении окислительного обмена колоноцитов. Независимое восстановление низкой доступности кислорода вернёт защиту. В определённом микробном сообществе замена бактерий на сопоставимые варианты, лишённые соответствующего преимущества дыхания, должна резко уменьшить различие между усилением и завершением регенерации. Если защита сохраняется при экспериментально фиксированных кислороде и бактериальном дыхании, гипотеза опровергнута.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.